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Podocytes are an important part of the glomerular filtration barrier and the key player
in the development of proteinuria, which is an early feature of complement mediated
renal diseases. Complement factors are mainly liver-born and present in circulation.
Nevertheless, there is a growing body of evidence for additional sites of complement
protein synthesis, including various cell types in the kidney. We hypothesized that
podocytes are able to produce complement components and contribute to the local
balance of complement activation and regulation. To investigate the relevant balance
between inhibiting and activating sides, our studies focused on complement factor H
(CFH), an important complement regulator, and on C3, the early key component for
complement activation. We characterized human cultured podocytes for the expression
and secretion of activating and regulating complement factors, and analyzed the
secretion pathway and functional activity. We studied glomerular CFH and C3 expression
in puromycin aminonucleoside (PAN) -treated rats, a model for proteinuria, and the
physiological mRNA-expression of both factors in murine kidneys. We found, that C3
and CFH were expressed in cultured podocytes and expression levels differed from
those in cultivated glomerular endothelial cells. The process of secretion in podocytes
was stimulated with interferon gamma and located in the Golgi apparatus. Cultured
podocytes could initiate the complement cascade by the splitting of C3, which can
be shown by the generation of C3a, a functional C3 split product. C3 contributed to
external complement activation. Podocyte-secreted CFH, in conjunction with factor I,
was able to split C3b. Podocytes derived from a patient with a CFH mutation displayed
impaired cell surface complement regulation. CFH and C3were synthesized in podocytes
of healthy C57Bl/6-mice and were upregulated in podocytes of PAN treated rats. These
data show that podocytes produce functionally active complement components, and
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could therefore influence the local glomerular complement activation and regulation.
This modulating effect should therefore be considered in all diseases where glomerular
complement activation occurs. Furthermore, our data indicate a potential novel role of
podocytes in the innate immune system.
Keywords: complement secretion, proteinuria, glomerulus, kidney, local regulation
INTRODUCTION
Proteinuric kidney diseases are very common in adult and
pediatric patients (1–3). In these diseases the glomeruli of
the kidneys are damaged and patients then suffer from severe
proteinuria. Podocytes (glomerular epithelial cells) are a critical
part of the glomerular filtration barrier, which also consists of the
glomerular basement membrane (GBM) and endothelial cells.
They show a complex, highly developed architecture and one of
their main tasks is to maintain the structure of the glomerular
filter. Structurally, podocytes form major processes and smaller
foot processes. The foot processes of neighboring podocytes
interdigitate with each other and form the slit-diaphragm, which
works as a semi-selective membrane and maintains the filtration
of urine. Thus, larger plasma proteins, such as albumin, are
held back in the serum. Podocytes also secrete proteins such
as VEGF, which not only maintains their own phenotype but
also maintains the fenestrated glomerular endothelium (4).
When podocytes are damaged, their foot processes are effaced
and the filter becomes leaky and patients then experience
proteinuria. Proteinuria also occurs in complement-associated
renal diseases (5, 6).
The complement system is an important player in the innate
immune system. It consists of more than 30 proteins (7). C3
activation is a central step in the initiation and amplification
of the system. All pathways result in the formation of a C3
convertase, which hydrolyses C3 to generate C3a and C3b. C3b,
together with factor B form another C3 convertase (C3bBb) and
together with another C3b fragment a C5 convertase (C3b2Bb),
which leads to the formation of the terminal complement
complex (TCC/C5b-9) (7). The C5b-9 complex can lead to
destruction of invading pathogens, foreign or apoptotic cells
or, in sublytic concentrations, to an activation of several cell
types. Furthermore, the occurring split products (e.g., C3a and
C5a) act as anaphylatoxins and recruit additional immune cells.
Beyond the long-known function of complement components in
the initiation of the complement cascade—especially C3—seem
to play a role in differentiation, proliferation and immune
response in T-cells and therefore link the innate to the adaptive
immunity (8).
Serum-based and membrane-bound complement inhibitors
regulate the activation of the complement system, to prevent
inappropriate activation. Complement factor H (CFH) is one
of the most important circulating regulators of the alternative
pathway. It serves as an essential cofactor for complement factor
I (CFI)-mediated C3b cleavage and has important tasks in the
decay of C3 convertase (9, 10). Therefore, C3 and CFH can be
hypothesized to be important protagonists in the initiation and
regulation of the complement cascade.
There is uncontrolled complement activation in a
number of renal diseases, notably atypical hemolytic uremic
syndrome (aHUS) (11), C3 glomerulopathy (10, 12, 13),
IgA nephropathy (14), and membranous nephropathy
glomerulopathy (10, 12, 13), IgA nephropathy (14), and
membranous nephropathy (6). The activation of the complement
system is thought to cause the system or an uncontrolled
regulation. Besides these diseases, which are directly triggered
by the systemic complement cascade, the complement system
can also be activated locally in non-primary immune-mediated
diseases, for example in Shiga toxin-associated hemolytic uremic
syndrome or kidney transplantation (15). This secondary
toxin-associated hemolytic uremic syndrome or kidney
transplantation (15). This aggravate severe renal damage.
The reason the glomerulus is particularly vulnerable to
unregulated systemic or local complement activation is not fully
clarified, yet.
Most complement proteins are produced in the liver and
circulate in the blood. In recent years, several extrahepatic
sources have been reported, including the kidney, brain,
lungs, and intestines. Several studies have shown these organs
can also produce small amounts of complement proteins,
which could contribute to local complement activation and
regulation (16–20). The kidney is one of the most important
extrahepatic sources. It has been shown that kidney-derived C3
contributes up to 10% of the circulating C3 (21). The local
production of complement proteins in the human kidney has
already been described in healthy individuals (22) and in those
with glomerular diseases (23–27). Primary renal cell culture
studies confirmed that mesangial, endothelial, and epithelial cells
are capable of synthesizing the activating circulating complement
proteins C3, C4, and factor B (28–32). CFH mRNA was also
detected in human glomeruli B (28–32). CFH mRNA was also
detected in human glomeruli (33). Sheerin and co-workers
demonstrated that local complement production is and that the
loss of local complement synthesis in this proteinuria model
prevents severe renal damage (34). Based on these findings,
a recently published study demonstrates that podocytes, key
players in the development of proteinuria, may themselves be one
important source of complement C3 in proteinuric diseases (35).
Furthermore, Zoshima and colleagues suggested a potential role
of podocyte derived CFH in clearing immune complexes in
a murine model of immune-complex glomerulonephritis (36).
However, the production of complement proteins by podocytes
remains controversial.
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Podocytes do not have any direct contact to serum-based
complement activation, which is in most cases the reason for
complement-mediated renal damage. Nevertheless, in special
circumstances the glomerular filtration barrier is leaky and allows
components of the blood to pass through, thus permitting contact
with podocytes. Additionally, local complement activation
could contribute to podocyte damage. Furthermore, there is a
growing body of evidence that podocytes may act as immune
modulating cells (37, 38). It has been shown that podocytes
express several toll-like receptors (TLR) (39–42), which are
regularly expressed in macrophages, T- and B-cells and B7-
1, which is expressed by B-cells or antigen-presenting cells.
Even though the role of TLR and B7-1 in podocytes is
highly debated, these data indicate that podocytes may have
additional roles beyond the stabilization of the glomerular
filtration barrier.
Therefore, we hypothesized that podocytes produce
functionally active complement proteins. While most studies
have focused either on the activating complement perspective
or the expression of regulating factors, we were interested in
both aspects to give a more complete overview. We investigated
the expression, functionality and secretion mechanisms of the
activating central complement factor C3 and the regulating CFH
in human podocyte cells and in a rat model of proteinuria.
MATERIALS AND METHODS
Antibodies, Proteins, and Serum
For Western blot antibodies against human C3 (goat, Pierce,
Thermo Scientific, Waltham, MA, USA, catalog number:
PA1-29715), CFH (goat, Calbiochem, Merck, Darmstadt,
Germany, catalog number: 341276), CD 46 (LS Bio, Seattle, WA,
USA, catalog number: 6754), C5b-9 (abcam, Cambridge, UK,
rabbit catalog number: ab55811), which seems to recognize a
neo-epitope on C9 and was used in the assay with rat-podocytes,
C5b-9 (mouse, Pierce, catalog number: MA5-28502) were used
in dilution 1:500–1,000. Mitogen-activated protein kinases
(MAPK) and β-actin were evaluated with rabbit antibodies
from Cell Signaling (1:100–500, Cell Signaling Technology,
Danvers, MA, USA, catalog numbers: 4668, 9101, 4631, 9252,
9102, 9212). For immunofluorescence antibodies against C3
(goat, Pierce, 1:100), CFH (goat, Calbiochem, 1:100), giantin
(rabbit, 1:100, abcam, catalog number: ab24586), tubulin
and laminin (both rabbit, 1:100, Sigma, St. Louis, MO, USA,
catalog numbers: T3526, L9393) were used. Nuclei were stained
with 4, 6-Diamidine-2-phenylindole dihydrochloride (DAPI)
(1:10,000, Sigma, St. Louis, MO, USA). IRDye conjugated
secondary antibodies for Western blot were obtained from
Licor (1:5,000, Lincoln, NE, USA). Appropriate secondary
antibodies for immunofluorescence were used from Thermo
Fisher (1:200–400, Waltham, MA, USA): Alexa Fluor, goat
anti-rabbit A488 and donkey anti-goat A594. Normal human
serum (NHS) was obtained from healthy laboratory staff
(10 persons, pooled and stored in aliquots at −20◦C).
Recombinant CFH, CFI, C3 and C3b were purchased from
Merck (Darmstadt, Germany).
Animal Experiments
Animals were housed in a controlled animal facility with free
access to water and standard animal chow. Experiments were
performed according to national and institutional animal care
and ethical guidelines and have been approved by the local ethical
committees at the Medical University of Hamburg-Eppendorf
and theMinistry of Health and Consumer Protection. Puromycin
aminonucleoside-induced nephropathy (PAN) was induced
in male Sprague–Dawley rats by intraperitoneal injection of
puromycin aminonucleoside in phosphate buffered saline (PBS)
(Sigma) as described (43). Urine was collected in metabolic cages
and proteinuria was measured in semi-quantitative conventional
dip sticks (Siemens, Berlin, Germany). Rats were euthanized on
day 28 and glomeruli were isolated: kidneys were encapsulated,
cortex was minced and sieved through a 90µm filter (BD,
Franklin Lakes, NJ, USA). The filtrate was sieved through a
53µm filter (BD) and glomeruli were removed from this filter
with cold PBS. Glomeruli were centrifuged at 1,000 rpm and
washed three times with 0.5% BSA in PBS (Sigma). Glomeruli
were frozen and kept at −80◦C until mRNA isolation. Small
parts of the kidney cortex were fixed in formaldehyde and
paraffin embedded for light microscopy. Sections 1–2µm were
stained with periodic acid-Schiff reagent (Sigma) according to the
manufacturer’s instructions.
Cell Culture
Primary human podocytes were transfected with temperature
sensitive SV40 and cultured as previously described (44). These
cells were used for all experiments with human podocytes. The
phenotype-differentiation of the cells was routinely controlled
in the microscope, and differentiation markers were analyzed
repeatedly as cited in the original manuscript (44). Cells
were used below passage 25. RPMI-media with glutamine was
supplemented with 10% fetal bovine serum (FBS) (both Gibco,
Life Technologies, Carlsbad, CA, USA) 100 U/ml penicillin,
0.1 mg/ml streptomycin (Gibco), and insulin, transferrin,
and sodium selenite mixture (ITS) (Sigma). Conditionally
immortalized human glomerular endothelial cells (CiGenC) were
produced from primary glomerular endothelial cells in a similar
way (45). Cells were used till passage 30, and provided with
the microvascular endothelial cell growth media EGM2TM-
MV (Lonza, Basel, Switzerland). Podocytes from an aHUS
patient with a known Arg1182Ser (G3546T) CFH mutation
were isolated from a nephrectomized kidney with informed
consent. This mutation affects the ability of CFH to bind to C3b
and heparin (46). Cells were isolated as described in (44) and
transfected with SV40.
To test protein secretion, differentiated podocytes were
washed with PBS, incubated in serum-free RPMI-media (SFM)
for 12–36 h and supernatant samples were taken. Human
interferon γ (IFNg) (R&D Systems, Wiesbaden, Germany) was
used with final concentrations from 0.1 to 100 ng/ml. Brefeldin
A (BFA) (Sigma), diluted in ethanol, was used at 5 ng/ml and
applied for 0–8 h.
Primary rat podocytes were cultivated from rats on embryonic
day 18. Kidneys were removed and washed twice with Hank’s
Balanced Salt Solution (HBSS) (Gibco). Papain replaced HBSS
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for enzymatic tissue digestion. After 30min of shaking at 37◦C,
digestion was stopped by three RPMI washes. Kidneys were
homogenized and passed through a 40µm cell strainer. Cells
were seeded at 20,000 cells/ml in RPMI 1640medium, containing
10% FBS, penicillin-streptomycin 100 U/ml, sodium pyruvate
and HEPES (all Gibco) at 37◦C. Differentiation occurred
after 2 weeks.
Quantitative PCR (qPCR) and Conventional
PCR
RNA was then isolated using an innuPrep RNA Mini Kit
(Analytik Jena, Biometra, Jena, Germany). RNA concentration
was measured with a NanoDrop ND-1000 spectrophotometer
(Thermo Scientific) (47). Twomicrograms of RNAwas converted
to cDNA using a cDNA synthesis kit (Life Technologies,
Carlsbad, CA, USA). qPCR was performed using SYBR green
(Sigma), according to manufacturer’s instructions on the
StepOnePlus real-time PCR system (Applied Biosystems, Life
Technologies) (95◦C 20 s, 60◦C 20 s, 72◦C 20 s). Sequences
were obtained from the Harvard Primer bank (http://pga.
mgh.harvard.edu/primerbank/) and purchased from Life
Technologies: for human CFH forward: CCTGATCGCAAG
AAAGACCAG and reverse: ACTGAACGGAATTAGGTC
CAAAT and for C3 forward: CCAAGAGCTCAAGGTGAGGG
and reverse: GGAACGGACAACGAGGACTT. The primer
sequences for rat CFH forward TTAGGCTGGCAGTTGGATCT,
CFH reverse TCCACCCATCTGCATCACAT C3 forward TCA
GGGTCCCAGCTACTAGT, and C3 reverse AGTCTCTTCACT
CTCCAGCC. Relative expression was determined as compared
to 18S controls.
In conventional (reverse transcriptase) PCR the following
primers from Life Technologies were used for C3: GCT
GCTCCTGCTACTAACCCA (forward), AAAGGCAGTT
CCCTCCACTTT (reverse), and for CFH: ACATTACTTC
ATTCCCGTTGTC (forward), ATACTCCAGTTTCCCATC
CCAA (reverse). PCR was accomplished using dNTPs (Life
Technologies), Dream Taq Polymerase-set (Fermentas,
Thermo Scientific), and Biometra Thermocycler (Labrepco,
Horsham, PA, USA) (94◦C 2min; 94◦C 1min, 60◦C 1min,
72◦C 1min x 34; 72◦C 2min). PCR-product was loaded onto
a 1.5% agarose gel with a 100 bp DNA Ladder (Biomol,
Hamburg, Germany). Additional primer sequences are shown in
Supplementary Table 1.
Immunofluorescence
Cells were grown on coverslips and fixed in 4% paraformaldehyde
(PFA) (Sigma), as previously described (48). Cells were blocked
with 3% bovine serum albumin, and permeabilized with 0.05%
Triton-X 100 (both Sigma), when needed. Images were taken
using the Leica confocal imaging spectrophotometer system
(TCS-SP2) or Leica TCS SP5 (Leica, Wetzlar, Germany).
Imaging was done with HCX PL FLUOTAR L 40x 0.6
objective lens with an optical zoom of 40, or with 63x
HCX PL APO Lbd. Bl. Oil. Microscopes were used at the
Wolfson Imaging Facility, University of Bristol or at the
University Microscope Imaging Facility (UMIF), University
Medical Center Hamburg-Eppendorf.
Western Blotting
Lysates were made with RIPA lysis buffer (Sigma), gel
electrophoresed (4–12% Gels, Invitrogen, Carlsbad, CA, USA).
Samples were boiled with 4×NuPAGE LDS Sample Buffer
(Invitrogen) and 0.1M dithiothreitol and blotted onto PVDF
(Merck Millipore) membranes as previously described (47,
48). Membranes were blocked with Odyssey R© Blocking Buffer
(Licor), 60min at room temperature prior to overnight
primary antibody incubation at 4◦C. Seeblue protein standard
(Invitrogen) was used as marker. Blots were washed and
incubated with appropriate secondary antibody before being
imaged using an Odyssey R© Clx Blot Scanner for IRDye-
antibodies. Densitometry was performed using Quantity One
software (v4.6.5, BioRad Laboratories, Hercules, CA, USA).
Cofactor Assay
Cofactor activity of secreted CFH was tested as previously
described (49, 50). In short, together with recombinant C3b
(final concentration 6µg/ml) and recombinant CFI (final
concentration 40µg/ml) podocyte supernatant (48 h in SFM)
was incubated at 37◦C. Samples were taken from the reaction
after 0, 5, and 20min. The addition of reduced SDS sample
buffer (Invitrogen) and boiling the samples for 10min stopped
the reaction. The samples were then separated by SDS
page, as described for Western blotting. C3 split products
were detected with anti C3 antibody. Recombinant CFH
(final concentration 33µg/ml) was used in the assay for
positive control.
Complement Challenge Assays
Human podocytes were washed in PBS prior to treatment with
30% rabbit serum in gelatin veronal buffer (GVB) (Sigma)
to set up antigen antibody complexes on the cell surface.
Complement was then activated by adding 20% CFH-deficient
human serum (Complement Technology, Tyler, TX, USA) in
GVB for 30min (51). Complement activation was then detected
by Western blot against C5b-9.
Rat podocytes were serum starved for 24 h and incubated
with anti-Fx1A-IgG (0.5 mg/ml), produced as previously
described (52). Briefly, sheep were immunized with isolated
brush border proteins, and serum was taken. IgG was isolated
with NabTM Spin Kit for antibody purification (Thermo
Scientific). After incubation for 20min at room temperature,
2.5% NHS, or 2.5% C3-depleted human serum (Calbiochem,
Merck Millipore), was added for 40min at 37◦C. Cells were
harvested for Western blotting.
C3 Convertase Assay
The C3 convertase (MicroVue, Quidel, San Diego, CA, USA)
assay was used following the manufacturer’s instructions. C3a
was measured at 450 nm using ultra-microplate reader EL808
(BioTek) and KC Junior software (v.1.41.6). A ratio of sample and
untreated control was calculated. Supernatants were taken from
plates with defined cell number and measured within 2 h.
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Factor H Re-synthesis Assay
Human podocytes were grown for immunofluorescence and
treated with trypsin (Gibco) 10µg/ml for 15min at 37◦C (53).
Cells were then incubated with SFM for 24 h.
Fluorescence in situ Hybridization
Kidneys from wildtype untreated C57BL/6 mice were dissected.
Kidneys were fixed in RNase free 4% PFA overnight at 4◦C and
cryopreserved in 30% sucrose, cryo-sectioned (14µm) and stored
frozen at −20◦C until use. The Affymetrix Quantigene View
RNA (Affymetrix, Santa Clara, CA, USA) in situ hybridization
systemwas used as permanufacturer’s instructions. Sections were
thawed and dried at 60◦C prior to Protease Q (20min, 40◦C)
treatment. Probes for CFH (accession No: NM_009888, Catalog
No VB1-16095) and C3 (accession No: NM_009778, Catalog No
VB1-13781), purchased from Affymetrix, were applied at 40◦C
for 4 h. A no probe control was run alongside each experiment.
The probe was labeled using fast red dye (Affymetrix). After
washing, slides were blocked in DAKO blocking reagent (Dako,
Hamburg, Germany). Rabbit anti-laminin antibody was diluted
in antibody diluting reagent (Dako) and incubated overnight
at 4◦C. Secondary antibody (1:200) diluted in antibody diluting
reagent, was added after washing, and incubated for 3 h. DAPI
nuclear counter stain was applied prior to mounting using
Fluoromount and then imaged using Leica SP5.
Statistical Analysis
Statistical analyses and graphs were carried out using PRISM
(Version 5, GraphPad Software). Results were considered
significant when p < 0.05. Images were analyzed with ImageJ.
RESULTS
Human Podocytes Express and Secrete
Complement Factors C3 and CFH in vitro
To evaluate the potential of podocytes to build complement
components we analyzed conditionally immortalized human
podocytes. Conventional reverse transcriptase PCR identified
mRNA for the activating key component C3 (PCR product 783
base-pairs [bp]) and also for CFH (320 bp) (Figure 1A). RNA
was also identified for the early activating complement proteins
C1q, C1r, C1s, C2, C4, C5; the alternative pathway activators
factor B, factor D, properdin and the regulators CD55, CD59,
and CD46 (MCP) (Supplementary Figure 1). As CFH is the
most important soluble inhibitor of the alternative pathway, and
C3 is a key component in early complement activation, our
subsequent work focused specifically on these two proteins. After
24 h of incubation in SFM, C3 and CFH were detected with
Western blots of the whole cell lysates and in the cell culture-
supernatant. Podocytes showed the expression of two products
of the C3 and the CFH-gene, which probably corresponds to
the α-chain of C3 and factor H-like protein (FHL) (Figure 1B).
Complement proteins for C2, C5, and the regulatory components
CFH, CD46, CD55, and CD59 were also detected (data not
shown). The expression of C3 and CFH could also be determined
in immunofluorescence (Figures 1C–E). Both proteins were
detected on the surface of non-permeabilized podocytes.
Production and Secretion of Podocyte
Complement Components Is an Active
Process
Secreted CFH circulates throughout the body and can bind to
most cells by binding to the cellular glycocalyx. This regulates
uncontrolled complement activation directly on the cell surface.
CFH glycocalyx binding sites can be degraded temporarily by
treatment with low dose trypsin (54). To see whether the
podocytes are capable of replacing removed CFH from the
surface we treated differentiated podocytes with low dose trypsin
to remove surface-bound CFH. Cells were then allowed to
recover in SFM. CFH was detected again on the surface of the
podocytes 24 h later, showing that these cells can produce and
replace CFH (Figure 2A).
IFNg has previously been shown to increase cellular
synthesis of complement proteins in a variety of cell lines (55–
57). Therefore, human podocytes were treated with IFNg
at different time points and concentrations. Stimulation
with IFNg significantly enhanced human podocyte mRNA
expression of C3 and CFH (Figure 2B). It also increased the
expression of both proteins in whole cell lysates (data not
shown). Furthermore, secreted C3 and CFH were increased
after stimulation with IFNg in a time- and dose-dependent
manner (Figures 2C–E). This suggests that podocytes are
capable of producing complement proteins as part of a
pro-inflammatory response.
Expression of Complement Factor C3 and
CFH Varies in Cultured Human Podocytes
and Glomerular Endothelial Cells
Podocytes are always affected in proteinuric glomerulopathies.
Nevertheless, within the glomerulus there are other cell types,
which can contribute to the local complement production.
Glomerular endothelial cells have direct contact with serum-
based complement activation and complement products, and we
have previously shown that podocyte-derived VEGF regulated
expression of protective complement regulators on glomerular
endothelial cells (51). To determine the cell specific production
of complement proteins, we compared the expression of
CFH and C3 in conditionally immortalized human glomerular
endothelial cells (CiGenC) (45) and podocytes (44). Cultivated
podocytes produced significantly more C3 mRNA, but less CFH
mRNA compared to endothelial cells (Figures 3A,B). At the
protein level for C3 and CFH, there was a slight, but non-
significant, higher expression of C3 in podocytes (Figures 3C,D).
The expression of CFH was significantly lower in podocytes
according to protein quantification (Figures 3C,E). Complement
activation may happen on any glomerular cell. Hence, the
secretion of produced complement products is important. From
the results in mRNA production, a comparison of secretion
of complement proteins C3 and CFH showed a significant
higher secretion of C3 (Figures 3F,G) and a lower secretion
of CFH (Figures 3F,H) in podocytes compared to endothelial
cells. Therefore, we could show that complement production
and secretion profiles may differ in different intraglomerular
cell types. As podocytes are the main target in PAN and in
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FIGURE 1 | Complement proteins C3 and CFH were expressed and secreted by unstimulated human podocytes (HPC). (A) Detection of PCR products for C3 (320
bp) and CFH (783 bp) in conventional reverse transcriptase PCR compared to -RT control (-RT, control of cDNA without addition of RT; bp, basepairs). (B) Protein
expression for C3 and CFH was determined by Western blot from whole cell podocyte lysate (HPC) and cell culture supernatant after 24 h in serum-free media (SFM).
Normal human serum (NHS, 1:1,000) and recombinant CFH or C3 were used as positive controls (rC3/rCFH, 1:1,000), SFM was used as negative control. In the C3
Western blot also the α-chain of C3 can be detected. The CFH gene has two protein products: CFH and factor H like-protein (FHL). Both are detected in this Western
blot in the podocyte cell lysate, in NHS and to a small extend in the cell culture supernatant (representative Western blots, n = 4). (C) Protein expression of C3 and (D)
CFH was confirmed in immunofluorescence on the surface of non-permeabilized cultured podocytes compared to isotype negative control (Neg-Ctrl) (E). (n = 3, C3
and CFH = green, nucleus = blue, scale bar 50µm, 40x).
most proteinuric glomerulopathies, we further analyzed the
complement expression in podocytes.
Podocyte-Derived CFH Is Efficient in
Complement Control
One of the major functions of CFH is its cofactor activity in
assisting CFI. With the help of CFH, CFI is able to split and
inactivate C3b. The generation of C3b is a key central step
in the activation of the complement system. It is required to
build the C5 convertase. Therefore, the inactivation of C3b is a
principal step in complement system regulation. The functional
activity of secreted CFH was tested in a cofactor assay. Podocyte
supernatant, which contains secreted CFH, was incubated with
recombinant CFI and C3b. Together with CFI the supernatant
was able to split C3b. This was evidenced by the reduction of the
C3b α-chain and the detection of the cleavage products of α′68-
and α′43-kD in Western blot (Figure 4A). This indicates that
podocyte-derived CFH is sufficient to act as a cofactor for CFI
cleaving C3b. CD46 as amembrane bound factor also is known to
split C3b together with CFI. There is an ongoing discussion about
shed CD46, which might in our case also act as a cofactor for
CFI and might contribute to the splitting of C3b.We could never
detect any CD46 in the cell culture supernatant (Figure 4B), even
though there was a positive signal in the cell lysate. There was
also no detectable induction of CD46 within the cell or in the
supernatant after stimulation with IFNg (different to CFH). CFH
seems to be crucial for the cofactor activity in the supernatant.
Nevertheless, the contribution of other complement regulators
cannot be excluded in this setting.
Finally, complement activation on normal human podocytes
and podocytes isolated from a patient with diagnosed aHUS was
compared. aHUS is a rare disorder of complement regulation,
which results in kidney impairment, thrombocytopenia and
anemia. A mutation in regulatory complement genes is found
in many patients with this disease. We used podocytes from
a patient with a known Arg1182Ser (G3546T) CFH mutation.
This mutation prevents CFH from binding to the cell surface
and partially to C3b (46). This is why cells from this patient
cannot regulate complement activation on the surface. In
a complement challenge assay, there was significantly more
C5b-9 on the surface of cells containing the CFH mutation,
compared to not diseased podocytes. This suggests that the
secreted podocyte CFH contributed to complement regulation
in the normal podocyte cell line but the mutated CFH
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FIGURE 2 | Production and secretion of C3 and CFH is an active and inducible process. (A) CFH was removed from the surface of cultured podocytes using low
dose trypsin (10µg/ml, 3min), the cells were then incubated in SFM for 24 h and the expression of CFH on the cell surface is determined in immunofluorescence
staining. The pictures are showing the detection of CFH (in red) before treatment with trypsin (left), immediately after the treatment (middle) and after 24 h recovery in
SFM (right) (n = 3, DAPI = blue, 60x, scale bar 25µm). (B–E) Expression and secretion of C3 and CFH was enhanced by interferon γ (IFNg). (B) mRNA expression of
C3 and CFH in human podocytes incubated 6 h with SFM (white bars), IFNg 1 ng/ml (gray bars), and IFNg 10 ng/ml (black bars) (*p < 0.05, **p < 0.001 compared to
expression in SFM). (C) Western blot against C3 (above) and CFH (below) of supernatant from podocytes incubated in SFM, IFNg 1 ng/ml or IFNg 10 ng/ml for 0–36 h.
Quantitative analysis of Western blots for the secretion of C3 (D) and CFH (E) from podocytes incubated in SFM, IFNg 1 and 10 ng/ml for 0 (white bars), 12 (light gray
bars), 24 (dark gray), and 36 (black bars) hours (*p < 0.05 and ***p < 0.001 compared to secretion with SFM, #p < 0.05 and ##p < 0.01 compared to incubation
with IFNg 1 ng/ml) Data are shown in mean and SD. Mann Whitney U-test, n = 5 independent experiments in (B,D,E).
from the aHUS cell line reduced the cells’ ability to regulate
complement (Figures 4C,D).
Cultured Podocytes Can Contribute to
Local Complement Activation
After the detection of C3 production in podocytes, we were
interested in investigating the possibility that podocytes secrete
other components of the complement cascade. In keeping with
the results from Li et al. (35), we were also able to detect other
components of the complement system in cultured podocytes
(Supplementary Figure 1). Nevertheless, we were not able to
detect mRNA for the later complement components C6, C7, C8,
or C9.
Even though the podocyte could not build a complete
C5b-9 complex, we wanted to study whether podocyte-
secreted C3 can take part in a local extracellular complement
reaction. We therefore induced complement activation on the
surface of cultured rat podocytes and analyzed the sublytic
complement activation. This model was used, as it is a
well-characterized cell culture-based model for complement
activation on podocytes. Sublytic complement activation is
known to induce the phosphorylation of MAPK (58, 59).
A scheme of the detailed experiment setting is shown in
Supplementary Figure 2. Primary rat podocytes were incubated
with anti-Fx1a antibodies, which were isolated from immunized
sheep (58) to establish antibodies, which were isolated from
immunized sheep (58) to establish activated with the addition
of NHS. The assembly of the C5b-9 complex was shown in a
Western blot. The blot showed a band in the range of C9, which
probably corresponds to a neo-epitope on C9, which can be
recognized by the antibody with the appearance of C5b-9. As we
could see no lysis or apoptosis after this treatment, we assumed
sublytic concentrations of C5b-9. To show the functionality of the
assumed C5b-9 complex formation, we analyzed a well-known
intracellular downstream pathway, the activation of MAPK.
This pathway is very important in podocytes’ differentiation
and proliferation.
To evaluate the influence of podocyte-derived C3, C3-
depleted serum was then used instead of NHS. We compared
the formation of C5b-9 and downstream activation of MAPK.
We confirmed the formation of C5b-9 (Figure 5A) and the
phosphorylation of p38a (Figures 5A,B), JNK (Figures 5A,C),
and ERK1/2 (Figures 5A,D) even in the group which was treated
with C3-depleted sera. These results suggest that cultured rat
podocytes are capable of secreting the missing C3 in order to
complete the cascade.
Furthermore, C3a was identified in the supernatant
(Figure 5E). C3a is one of the proteins formed by the cleavage of
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FIGURE 3 | Expression of complement factor C3 and CFH is different in cultured podocytes and glomerular endothelial cells. Conditionally immortalized human
podocytes (HPC) and human glomerular endothelial cells (CiGenC) were compared for their expression of C3 and CFH on mRNA- and protein-level and secretion of
both proteins. (A) mRNA-expression of C3/18S and (B) CFH/18S in HPC (white bars) and CiGenC (black bars) (n = 12). Protein expression of C3 and CFH was
analyzed in Western blot (C) of whole cell lysates. Densitometry of C3 (D) and CFH (E) in HPC (white bars) and CiGenC (black bars) normalized to expression of beta
(b)-actin (n = 6). Secretion of C3 and CFH into cell culture supernatant was tested in similar numbers of seeded cells and analyzed in Western Blot (F). Western blot
densitometry of C3 (G) and CFH (H) from HPC-supernatants (white bars) and CiGenC-supernatants (black bars) (n = 6) Recombinant C3 and CFH were used as
positive controls (Pos-Ctrl) in (C,F) in dilution 1:1,000. Data (relative expression) are shown in mean and SD in (A,B,D,E,G,H), **p < 0.01, ***p < 0.001, Mann Whitney
U-test.
C3. C3a formation occurs through activation and cleavage of C3,
which is catalyzed by C3 convertase. This indicates that, under
specific circumstances, podocytes are capable of producing C3
splitting enzymes, e.g., a C3 convertase.
C3 and CFH Are Processed in Golgi
Apparatus
To confirm that the cultured podocyte can actively secrete
complement components, we investigated the intracellular
localization of C3 and CFH. Podocytes were co-stained for C3,
CFH, and the Golgi apparatus marker giantin. CFH and C3 co-
localized with giantin (Figure 6A, detailed split images can be
seen in Supplementary Figure 3). Negative controls showed no
staining (data not shown). Brefeldin A (BFA), a general inhibitor
of exocytosis, leads to a retrograde transport of proteins and a
disruption of the Golgi apparatus. Incubation with BFA reduced
the secretion of C3 in podocytes (Figures 6B,C). The influence of
BFA on CFH secretion could not be measured, because CFH was
barely detectable in the supernatant before 12 h of incubation,
and treatment with BFA for longer than 8 h resulted in apoptosis
of these cells. Treatment with BFA for 4 h led to collapse of the
Golgi stacks and C3 and CFH moved from the perinucleus to a
more diffuse cytoplasmic distribution (Figure 6D). These results
indicate that complement proteins are processed in the Golgi
apparatus in podocytes.
To determine the specific transportation pathways, we
analyzed the co-localization of complement C3 and CFH
with microtubules. Microtubules play an important role in
intracellular transportation pathways and can be visualized by the
staining of tubulin. We found a clear co-localization of C3 and
CFH with tubulin. C3 and CFH were partly found in small round
structures, which might be transportation vesicles (Figure 6E).
These results indicate that podocyte-produced complement
proteins are processed in the Golgi apparatus, packed in secretion
vesicles and moved to the surface along the microtubules.
Glomerular C3 and CFH Is Upregulated in
PAN
To evaluate if glomerular damage also results in the regulation
of complement genes, PAN was induced in male Sprague–
Dawley rats. PAN is a well-characterized and established model
to mimic proteinuric diseases. Puromycin induces injury of the
podocyte actin cytoskeleton (60) leading to sustained foot process
effacement, podocyte loss, glomerular sclerosis, and proteinuria.
As we were interested in the balance between C3, the central
activating component, and CFH, the most important inhibitor of
the alternative pathway, we investigated glomerular damage and
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FIGURE 4 | Podocyte-secreted CFH functionally active. Functionality of secreted CFH was tested in a cofactor assay and in a C5b-9 deposition assay in podocytes
with lost CFH derived complement control. (A) Cofactor assay: CFH together with CFI can split recombinant C3b. Split products with a size of 68 and 43 kDa can be
detected in Western blot against C3. Podocyte supernatant with added CFI was able to cleave added recombinant C3b. Positive control: C3b, CFI and CFH were
added to serum free media (SFM) in supersaturated amounts, leading to immediate cleavage of C3b (illustrated by the appearance of the cleavage products of α′68-
and α′43 kD). There is no detection of any cleavage products after the incubation of C3b and CFI, or C3b and CFI in SFM (left part). When C3b and CFI are added to
podocyte supernatant, C3b split products can be detected. (B) Podocyte lysate (HPC) shows a clear signal for CD46 as a membrane bound complement regulator,
but did not shed CD46 into the supernatant. The treatment of podocytes with interferon γ (IFNg, 10 ng/ml, 24 h) did not result in an induction of CD46 in the cell lysate
or enhanced shedding in the cell culture supernatant (representative Western blot of 3 independent experiments). (C,D) The deposition of terminal complement
complex C5b-9 was compared on normal human podocytes and podocytes from a patient suffering from atypical hemolytic uremic syndrome (aHUS). Patient’s CFH
was not able to bind to the cell surface. Complement activation was achieved by the induction of cell surface antigen-antibody binding followed by CFH-deficient
human serum. Deposition of C5b-9 was assessed in a Western blot. (C) Western blot against C5b-9 on normal human podocytes (Ctrl) and aHUS patient’s
podocytes. (D) After complement activation aHUS podocytes (black bar) showed increased C5b-9 deposits compared to control cells (white bar) (relative deposition
of C5b-9 related to actin, ***p < 0.001, Mann Whitney U-test, n = 4 independent experiments. Data are shown in mean and SD. (D) Representative Western blots of
at least n = 3 experiments are shown in (A–C).
mRNA expression of these two complement proteins in isolated
glomeruli. After 14 days, PAN rats developed severe proteinuria
(data not shown). Staining with Periodic Schiff Acid showed
massive sclerosis and glomerular damage (Figure 7A). In these
studies, we confirmed the results of Li et al. (35), concerning
the glomerular upregulation of C3 mRNA in PAN (Figure 7B).
In addition, we detected an increased induction of CFH in
comparison to H2O-treated controls (Figure 7C). As podocytes
are the main target in PAN, we were extremely interested in the
ability of podocytes to produce these critical opposing players in
the complement system.
Podocytes Expressed CFH and C3 in vivo
Unfortunately, we were not able to show any positive staining
for C3 or CFH protein in podocytes in murine or human
tissue (data not shown). Therefore, to prove the origin of CFH
and C3 production in glomeruli in vivo, fluorescence in situ
hybridization (FISH) studies were performed in glomeruli of
healthy C57Bl/6 mice. C3- and CFH-mRNA was identified in
glomeruli of healthy C57Bl/6 mice (Figures 7D,E). Negative
control showed no staining of the mRNA signal (Figure 7F).
The mRNA of C3 and CFH partially co-localized with podocyte
nuclei. These findings are clear evidence that local glomerular
complement production occurs within the glomeruli and in
podocytes. Furthermore, there was C3 and CFH in tubular cells,
indicating that podocytes are not the only source in the kidney.
DISCUSSION
Podocytes are complex differentiated cells that are essential
for the functionality of the glomerular filtration barrier and
renal function. Damaged podocytes have very limited potential
for recovery and regeneration (61). Therefore, the integrity
of the podocyte and the resistance against damage due to
local complement activation or against invading pathogens
is important. The complement system is a crucial part of
the innate immune system. It helps with the elimination of
invading microorganisms and the removal of apoptotic cells.
Nevertheless, it has also been shown to contribute to a growing
list of inflammatory conditions (62). The kidney is particularly
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FIGURE 5 | Podocyte-produced C3 contributes to complement activation. (A–D) Primary rat podocytes were treated with anti-Fx1a antibodies, followed by
incubation with NHS as a source of complement factors. The formation of the terminal complement complex C5b-9 and the phosphorylation of mitogen activated
protein kinases (MAPK), were measured in Western blots. To evaluate the influence of C3 secreted from podocytes, NHS was replaced by C3-depleted serum.
Therefore, any formation of C5b-9 or phosphorylation of MAPK must involve C3 originating from podocytes. (A) Western blot confirming the formation of C5b-9 (first
row) after treatment with anti-Fx1a antibodies and the addition of NHS or C3-depleted (depl.) serum. Both treatments induced an enhanced phosphorylation of p38a
(second row), JNK (fourth row) and ERK (sixth row), while the total unphosphorylated contents of these proteins showed no changes at all (third, fifth and seventh
row). Quantification of 6 independent experiments are shown in densitometry for (B) phosphorylated p38α, (C) phosphorylated JNK and (D) phosphorylated ERK.
Data are expressed in mean and SD. Phosphorylated forms are normalized to total protein content. Mann Whitney U-test, *p < 0.05 compared to aFx1a. (E) The
concentration of C3a in cell culture supernatant of unstimulated human podocytes was measured by ELISA (*p < 0.05, compared to 0 h, #p < 0.05 compared to
12 h, §p < 0.05 compared to 24 h, Data are shown in mean and SEM, Mann Whitney U-test, n = 5 independent experiments).
sensitive to complement-mediated damage. In several systemic
complement disorders, for example in diseases like aHUS or
systemic lupus erythematosus (SLE), the kidney is a particular
target. The reason for the kidney’s unique susceptibility to
complement-induced damage is not yet fully elucidated, but
it could be influenced by its structural organization and
functional duties (63). Renal perfusion contributes to the
constant contact of the glomerulus with several circulating toxins
or immune cells.
With the podocyte at the center of all forms of proteinuria,
these cells were analyzed to determine their potential to produce
complement proteins. Our studies showed that podocytes not
only express and store complement proteins, they can also secrete
functionally active C3 and CFH, which is enhanced by IFNg,
an immune-stimulating protein. Therefore, it is probable that
podocytes influence local complement activation in situations
of immune-related challenge, for example in infection and
inflammation. The need for resistance of kidney cells against
invadingmicroorganismsmight be a good explanation for kidney
cells’ potential to express complement activating components.
The kidney seems to have an activated complement profile under
unstimulated conditions. These complement proteins might
serve to remove immune complexes and provide protection
against microorganisms of the urinary tract (64). Podocytes,
sitting on the outside of the glomerular filtration barrier, are
especially prone to contact with invasive pathogenic substances.
Therefore, the expression of C3, as the key player in complement
activation and particularly the secretion of C3a as a potent
anaphylatoxin, could be crucially useful. On the other hand, the
podocyte-produced C3 could also contribute to activation of the
system due to a systemic complement disorder or secondary
complement activation in inflammatory circumstances. This
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FIGURE 6 | CFH and C3 were localized in the Golgi apparatus and secretion was dependent on normal Golgi function. (A) Podocytes were stained for C3 (left, green)
and CFH (right, green) and with an antibody against giantin, a Golgi apparatus protein (red). Co-localization is shown in yellow for both proteins (40x, scale bar 25µm).
(B,C) Podocytes were treated with Brefeldin A (BFA), a general exocytosis inhibitor. The secretion of C3 into the cell culture supernatant was tested in Western blot,
after treatment with BFA 5µg/ml compared to SFM. (B) Western blot against C3 and quantification (C) after 0 (white bars), 2 (light gray bars), 4 (dark gray bars), and
8 h (black bars). Data are shown in mean and SD, Mann Whitney U-test, ***p < 0.001 compared to SFM, n = 3. (D) Podocytes were treated with BFA and stained for
giantin (left panel), C3 (middle), and CFH (right) before (SFM) and after 4 h treatment: The regular Golgi structure in podocytes after incubation in SFM (above),
dissolves after treatment with BFA (below). The intracellular distribution of C3 and CFH changes after BFA treatment from a mostly perinuclear (above) to a more
diffuse cytoplasmic staining after the disruption of the Golgi apparatus (below). (E) Immunofluorescence staining of C3 (above) and CFH (below) stained in red,
co-localized with staining of tubulin (green), an important component of microtubules, which regulate transportation on cells. C3 and CFH were partly localized in small
round structures (circles), which might be equivalent to secretion vesicles. Representative pictures of at least n = 3 independent experiments are shown in (A,D,E),
scale bar 25µm, 40x.
might explain why podocytes are damaged in complement
mediated diseases like C3 glomerulonephritis or aHUS.
It has been described previously how several complement
components were locally produced by parenchymal cells of the
glomeruli and in tubules. Li et al. (35) have already shown
a glomerular C3 upregulation in an experimental proteinuric
model. We confirmed their findings that podocytes are one
source of C3 mRNA using FISH and indirectly via glomerular
upregulation in PAN treated rats. We also showed that podocytes
in culture are able to actively secrete C3, which contributed to
external experimental complement activation. The detection of
C3a indicated that podocyte-secreted C3 is functionally active
and can induce complement activation. This might occur during
local inflammatory conditions. With the generation of C3 and
C3a, podocytes could activate complement upstream of C5b-
9. Additionally, the secreted complement proteins could be
washed into the urinary space. Several complement proteins have
already been detected in urine (14, 65–72). The occurring protein
leak in situations of proteinuria was previously thought to be
responsible for this detection. Others have suspected production
of C3 by tubular cells (73). Our work also detection. Others have
suspected production of C3 by tubular cells (73). Our work As has
already been shown, kidney cells, and podocytes in particular, are
affected directly by complement activation (74, 75). Therefore,
defending mechanisms are essential to prevent permanent
damage. Podocytes, like several other cells, produce membrane-
bound regulators to protect themselves from complement
attack (76). Membrane-bound regulators, such as CD46, CD55,
and CD59, protect the respective regulator-expressing cell from
the assembling of complement activation products on the
cell surface. Additionally, there are circulating complement
regulators like CFH, which predominantly regulate complement
activation in the alternative pathway. CFH molecules are mainly
produced in the liver. However, we also detected the expression
of CFH in vitro and in vivo in podocytes. The podocyte-
derived CFH acted as a cofactor for CFI to cleave C3b in a
cofactor assay, showing that it was functionally active. A very
important other mechanism of CFH in complement control is
the decay of the convertase, which was not tested in detail in this
study. Nevertheless, in a setting with functionally defective CFH,
podocytes were not able to prevent the adhesion of C5b-9 during
the complement attack.
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FIGURE 7 | Glomerular C3- and CFH-mRNA is upregulated in puromycin aminonucleoside-induced nephropathy (PAN) in rats and C3 and CFH is expressed in
glomeruli of healthy mice. Rats were treated with puromycin aminonucleoside to induce PAN. Rats were euthanized at day 28, kidneys were obtained and glomeruli
were isolated. (A) Periodic Acid Schiff (PAS) staining in kidneys from controls (left) and PAN (right) (representative pictures, n = 3, scale bars 50µm, 40x). (B)
Expression of glomerular C3 mRNA and (C) glomerular CFH-mRNA in PAN (black bars) compared to controls (white bars). Ribosomal 18S-mRNA was used as an
internal control and data are expressed in mean 1CT ± SD in (B,C). *p < 0.05, Mann-Whitney U-test; n = 3–5. (D–F) Fluorescence in situ hybridization of C3 (D),
CFH (E), and a “no probe” negative control (Neg-Ctrl) in healthy mice (F). C3 and CFH (red dots) co-localized with cell nuclei (blue), basement membrane was stained
with laminin (green). Cells, which were outside of the basement membrane, were counted as podocytes. Podocyte expression of C3- and CFH-mRNA is shown in the
enlarged frames. Arrows mark tubular expression of C3 and CFH. Figures show representative pictures of at least three independent experiments, scale bar
25µm, 60x.
It could be argued that aHUS is exclusively an endothelial cell
disorder, but proteinuria can be a presenting clinical feature of
this disease, confirming that podocytes are affected early in the
disease (77). The detection of impaired podocyte CFH in one
aHUS patient (78) supports the importance of podocyte-derived
CFH in protecting the glomerulum from complement mediated
injury. Further, other researchers have recently suggested that
podocyte dysfunction can occur in acquired and genetic forms
of complement-mediated aHUS, suggesting that podocytes do
indeed play a role in this disease (79). Loss of local complement
regulation may be important for those patients who require
a second hit before manifestation of the disease. The local
production of CFH also seems to be essential in SLE, where
it is responsible for processing the immune complexes. The
deficiency of CFH results in an accelerated development of lupus
nephritis in an animal model for SLE (80). Furthermore, an
important role of podocyte derived CFH development of lupus
nephritis in an animal model for SLE (80). Furthermore, an
Another indication that the podocyte is a local source for CFH
is the detection of CFH in urine from healthy individuals (81).
CFH, a 150 kDa serum protein, would not normally undergo
ultrafiltration. In this context, CFHmay be produced on demand
locally and play a regulatory role in urine even under normal
circumstances. There is evidence for the local importance of
CFH in other diseases as well. In membranous nephropathy,
the ratio of urinary C5b-9 to CFH was associated with active
glomerular disease highlighting the protective role of this protein
in disease (81). Elevated urinary CFH levels have also been
detected in other glomerulopathies (70, 82). In our opinion
podocytes, in addition to other glomerular cells, are one source
of CFH. Another source of this urinary CFH could be the
tubular cells, which showed a positive CFH and C3 mRNA
signal in FISH. Nevertheless, in glomerular diseases tubular
cells are usually damaged later, while proteinuria indicates that
glomerular cells are affected early on. This local glomerular
interplay could be important concerning CFH production, since
it has a complement regulatory role on basementmembranes that
do not express other complement regulators (83).
Endothelial cells in culture can produce and secrete
complement factors such as C3 and CFH and can contribute
to local glomerular complement activation. However, there was
a variation in the level of expression in both factors between
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podocytes and glomerular endothelial cells, suggesting distinct
levels of regulation within different sections of the glomerulus.
Even though this different expression level was described only
in vitro, it indicates that glomerular cells might have different
individual tasks. We could hypothesize that they have to work
together to organize appropriate local complement activation.
These glomerular cell types have to ensure that there is a distinct
balance between activation and regulation of the cascade to
prevent uncontrolled kidney damage. Our previous work has
shown that there is a synergistic role between podocytes and
endothelial cells in glomerular complement regulation (51).
The different expression levels of complement factors lead
to another additional consideration: it has already been shown
that there is an important crosstalk between podocytes and
endothelial cells, which occurs particularly with regards to
VEGF (4). On one hand, the production of different factors
in different cells could contribute to complement activation
on different levels. On the other hand, the secretion of
complement factors might have additional novel roles for other
surrounding cells. There is a growing body of evidence that
C3 and C3a have roles extending beyond those of complement
system activation. Rather than being just a pro-inflammatory
effector system, complement is emerging as a central player
in cell differentiation, proliferation, repair and induction in
T-cells (84). The complement system is not only thought
to repair and induction in T-cells (84). The complement
system is not only thought intracellular complement—the
so called complosome—seems to have an impact on normal
cell physiology (85). Nevertheless, the meaning of local on
normal cell physiology (85). Nevertheless, the meaning of local
endothelial cells has not yet been uncovered. Even though, the
podocyte might not be the only or main source of kidney derived
complement proteins, it is not known, whether even low amounts
of locally produced activating or regulating factors might have a
relatively higher impact on local inflammation. The hypothesis,
why we were not able to show any positive protein signal for C3
or CFH, might be due to the low expression of both proteins
in podocytes compared to other cell-types or the concentration
measured systemically in the blood. Another explanation might
be that both proteins are not stored in huge amounts within
the cells and might be secreted rapidly to regulate the local
complement activation.
However, one of the most important conclusions resulting
from our findings is that the podocyte seems to have more
tasks than just mechanistic stabilization of the glomerular filter.
There is a growing body of evidence that podocytes may
act as immune modulating cells (38). Even though they are
affected in this disease themselves, podocytes seem to play an
important role in the regulation of complement factors that
may prevent nephritis in SLE; they also influence innate and
adaptive immunity. It has been shown that isolated glomeruli
express TLRs, for example TLR4 (40), which is associated with
the development of lupus nephritis. The activation of TLR4
(e.g., with lipopolysaccharide) induces the expression of various
cytokines (e.g., CCL2, CCL7, CXCL1, CXCL5, CCL3, CCL5,
and more) (37, 38). Therefore, the podocyte seems to be able
to create an inflammatory milieu in certain circumstances.
Additionally, podocytes express the receptor for advanced
glycation end products (RAGE), which is important in several
immune reactions and which is upregulated in ADR-induced
nephropathy (86). They are also capable of expressing the
NLRP3 inflammasome, which is activated in the development of
proteinuria in lupus nephritis (87).
With our findings we demonstrated that podocytes have a role
beyond a purely stabilization function in the glomerulus. The
podocyte might act as an immune modulating, and especially
local complement modulating, cell. In states of proteinuria,
primary or secondary complement activation can occur within
the glomeruli and podocytes seem to be able to contribute
to this complement activation by production of activating
or inhibitory complement components. Even though there is
increasing knowledge about the involvement of complement in
kidney diseases, the new role of the podocyte as the local source of
complement activators and regulators requires additional study
in all causes of glomerular complement activation. Furthermore,
our results underline a possible role of the podocyte as an
immune modulating cell.
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Supplementary Figure 1 | Unstimulated human podocytes (HPC) express
mRNA for various complement factors in conventional PCR (-RT, control of cDNA
without addition of RT; bp, base pairs).
Supplementary Figure 2 | Schematic presentation of the assumed underlying
mechanisms in the complement challenge assay. (A) The binding of anti-podocyte
antibodies leads to the activation of the complement cascade via the classical
pathway (after the addition of normal human serum as a complete source of
complement factors). The complement activation and building of C5b-9 induces
sub-lytic damage in this in vitro model, which can be shown with the detection of
phosphorylation of mitogen activated protein kinases (MAPK). (B) The use of
C3-depleted serum did not prevent the phosphorylation of MAPK, which proves
that podocytes derived C3 replaces external C3.
Supplementary Figure 3 | Detailed spilt images: Podocytes were stained for C3
and CFH (green) and with an antibody against giantin, a Golgi apparatus protein
(red). Co-localization is shown in yellow for both proteins (40x, scale bar 25µm).
Supplementary Table 1 | Primer sequences conventional PCR, primers were
obtained from Sigma Aldrich.
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